INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Lobbying registrant
TY

TARPLIN, DOWNS & YOUNG, LLC

Open in network
Disclosed transactions0
Buys / sells0 / 0
Max Insider Score—
Connections19with evidence

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

  • Lobbied forevidence
    GILEAD SCIENCES, INC.LDA Q2 2026 second quarter · Budget/appropriations, Health issues, Medicare/Medicaid · Aug 26, 2026
  • Lobbied forevidence
    Amneal Pharmaceuticals, Inc.LDA Q2 2026 second quarter · Health issues, Budget/appropriations · Aug 26, 2026
  • Lobbied forevidence
    Option Care Health, Inc.LDA Q2 2026 second quarter · Budget/appropriations, Medicare/Medicaid · Aug 26, 2026
  • Lobbied forevidence
    Accenture plcLDA 1T 2026 first quarter · Health issues, Medicare/Medicaid, Budget/appropriations · Aug 26, 2026
  • Lobbied forevidence
    AMGEN INCLDA Q1 2026 first quarter · Health issues, Medicare/Medicaid, Budget/appropriations · Aug 26, 2026
  • Lobbied forevidence
    AbbVie Inc.LDA Q2 2026 second quarter · Medicare/Medicaid, Budget/appropriations, Health issues · Aug 26, 2026
  • Lobbied forevidence
    Sarepta Therapeutics, Inc.LDA Q1 2026 first quarter · Budget/appropriations, Health issues, Medicare/Medicaid · Aug 26, 2026
  • Lobbied forevidence
    QUEST DIAGNOSTICS INCLDA Q2 2026 second quarter · Health issues, Medicare/Medicaid, Budget/appropriations · Aug 26, 2026
  • Lobbied forevidence
    Jazz Pharmaceuticals plcLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • Lobbied forevidence
    NEUROCRINE BIOSCIENCES INCLDA Q1 2026 first quarter · Health issues, Medicare/Medicaid, Budget/appropriations · Aug 26, 2026
  • Lobbied forevidence
    Phreesia, Inc.LDA Q2 2026 second quarter · Budget/appropriations, Health issues, Medicare/Medicaid · Aug 26, 2026
  • Lobbied forevidence
    Amylyx Pharmaceuticals, Inc.LDA Q1 2026 first quarter · Health issues, Medicare/Medicaid · Aug 26, 2026
  • Lobbied forevidence
    ELI LILLY & CoLDA Q2 2026 second quarter · Medicare/Medicaid, Budget/appropriations, Health issues · Aug 26, 2026
  • Lobbied forevidence
    NovoCure LtdLDA Q2 2026 second quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
  • Lobbied forevidence
    NOVARTIS AGLDA Q2 2026 second quarter · Medicare/Medicaid, Trade, Budget/appropriations, Health issues · Aug 26, 2026
  • Lobbied forevidence
    Immix Biopharma, Inc.LDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • Lobbied forevidence
    ASTRAZENECA PLCLDA Q1 2026 first quarter · Budget/appropriations, Medicare/Medicaid, Health issues · Aug 26, 2026
  • Lobbied forevidence
    BRISTOL MYERS SQUIBB COLDA Q1 2026 first quarter · Medicare/Medicaid, Health issues, Budget/appropriations · Aug 26, 2026
  • Lobbied forevidence
    VERTEX PHARMACEUTICALS INC / MALDA Q2 2026 second quarter · Budget/appropriations, Health issues, Medicare/Medicaid · Aug 26, 2026
Data sources
SEC FORM 436m ago
HOUSE PTR36m ago
SEC 13F36m ago
ROBINHOOD CHAIN36m ago